Insights

Home » Insights » Insights Intercept Blood System

Categories

see all
Cerus 06/07/2018

2 million Swiss francs to develop a whole blood PI system in Africa

The Swiss Red Cross Humanitarian Foundation has awarded a grant of 2 million Swiss Francs to Cerus, the University Hospital of Basel, and the Swiss Transfusion SRC to complete the necessary clinical studies to develop a whole blood pathogen inactivation system for use in Africa. 
04/07/2018

Missing Type

What if the blood groups, A, B and O were to disappear suddenly from everyday life?

Every second, thanks to blood donors, three transfusions are given around the world. But global blood services are highlighting a 28% drop in new donors compared to 10 years ago.

Ask an Expert

Do you have questions about the INTERCEPT™ Blood System, blood safety or blood transfusions? The INTERCEPT team has plenty of knowledge and expertise.

Ask an Expert

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 00157 v43.0